Claims for Patent: 7,888,490

Summary for Patent: 7,888,490

Title:	Process for the preparation of non-toxic anthrax vaccine
Abstract:	Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B. anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF of EF are incorporated into the vaccines. An ideal vaccine against anthrax should contain PA, LF and EF together, but this combination would be toxic. Therefore, the biologically inactive mutant preparations of PA, LF and EF may be used together for better immunoprotection. The present invention describes the method for generation of recombinant vaccine against anthrax, comprising of non-toxic, mutant anthrax toxin proteins. The procedure involves site-directed mutagenesis of the native genes of the toxin proteins, the expression and purification of the mutant proteins and finally characterization of these proteins.
Inventor(s):	Bhatnagar; Rakesh (New Delhi, IN), Gupta; Pankaj (New Delhi, IN), Batra; Smriti (New Delhi, IN), Chauhan; Vibha (New Delhi, IN), Singh; Aparna (New Delhi, IN), Ahuja; Nidhi (New Delhi, IN), Kumar; Praveen (New Delhi, IN)
Assignee:	Centre of Biotechnology Jawaharlal Nehru University (New Delhi, IN)
Application Number:	10/497,673
Patent Claims:	1. A recombinant DNA construct for expressing mutagenized toxin protein of Bacillus anthracis comprising: A) an expression vector, and B) a DNA fragment comprising a gene encoding mutant type Protective Antigen (PA), mutant type Lethal Factor (LF) or mutant type Edema Factor (EF), or a combination thereof wherein the DNA fragment comprises a non-native sequence that results from amplifying at least one of (i) a gene encoding native Protective Antigen (PA) with a primer selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, and 6; (ii) amplifying a gene encoding native Lethal Factor (LF) with a primer selected from the group consisting of SEQ ID NO: 20, 21, 22, 23, 24, 25 and 26; and (iii) amplifying a gene encoding native Edema Factor (EF) with a primer selected from the group consisting of SEQ ID NO: 27, 28, 29 and 30. 2. A recombinant DNA construct as claimed in claim 1, wherein said expression vector is a prokaryotic vector. 3. A recombinant DNA construct as claimed in claim 2, wherein said prokaryotic expression vector is pQE30. 4. A recombinant DNA construct as claimed in claim 3, wherein said prokaryotic expression vector contains T5 promoter and 6X histidine tag. 5. A mutagenized PA, LF or EF anthrax toxin protein of Bacillus anthracis, expressed by the recombinant DNA construct of claim 1, wherein the protein possesses immunogenic properties. 6. A method of producing a mutagenized PA, LF or EF anthrax toxin protein, wherein the method comprises the following steps: a) producing a mutant gene encoding a mutant toxin protein PA, LF or EF by amplifying a native PA, LF or EF template in a polymerase chain reaction using a primer selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30 to form mutant polymerase chain reaction products, b) treating the mutant polymerase chain reaction products along with the native template from step a) with an enzyme to cleave the native template of said polymerase chain reaction products to form mutant products, c) transforming a prokaryotic host with said mutant products of step b to cause the prokaryotic host to express the mutagenized PA, LF or EF anthrax toxin protein, and d) purifying the expressed mutagenized PA, LF or EF anthrax toxin protein. 7. A method as claimed in claim 6, wherein the prokaryotic host is an E. coli strain. 8. A method as claimed in claim 6, wherein said enzyme is DpnI enzyme that specifically cleaves fully methylated target sequence G.sup.me6 ATC. 9. A method as claimed in claim 6, wherein saidm--mutant gene is cloned in a pQE30 expression vector under the control of T5 promoter and 6X histidine tag fusion. 10. A method as claimed in claim 6, wherein said purification is carried out using Ni-NTA affinity chromatography. 11. An anthrax vaccine comprising a mutant toxin protein of Bacillus anthracis encoded by the recombinant DNA construct of claim 1, said vaccine comprising a mutant toxin protein PA, LF or EF, or a combination thereof. 12. An anthrax vaccine comprising one or more mutagenized anthrax toxin proteins of claim 5, in combination with a toxin protein of Bacillus anthracis of wild-type PA or wild-type LF or wild-type EF. 13. A mutagenized PA anthrax toxin protein produced by the method of claim 6. 14. A mutagenized LF anthrax toxin protein produced by the method of claim 6. 15. A mutagenized EF anthrax toxin protein produced by the method of claim 6. 16. A recombinant DNA construct as claimed in claim 1, wherein the DNA fragment comprises a non-native sequence that results from amplifying a gene encoding native Protective Antigen (PA). 17. A recombinant DNA construct as claimed in claim 1, wherein the DNA fragment comprises a non-native sequence that results from amplifying a gene encoding native Lethal Factor (LF). 18. A recombinant DNA construct as claimed in claim 1, wherein the DNA fragment comprises a non-native sequence that results from amplifying a gene encoding native Edema Factor (EF).

Details for Patent 7,888,490

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2021-12-05